Chemours (NYSE:CC) Earning Somewhat Favorable Press Coverage, Report Finds

News headlines about Chemours (NYSE:CC) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chemours earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the specialty chemicals company an impact score of 46.6331421027877 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Several analysts have recently weighed in on the company. Barclays reiterated a “buy” rating and set a $60.00 target price on shares of Chemours in a research report on Wednesday, December 6th. Zacks Investment Research downgraded shares of Chemours from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Goldman Sachs Group downgraded shares of Chemours from a “buy” rating to a “neutral” rating and set a $55.00 target price for the company. in a report on Wednesday, December 6th. Morgan Stanley initiated coverage on Chemours in a research note on Tuesday, January 30th. They set an “equal weight” rating and a $57.50 price target on the stock. Finally, Jefferies Group upped their target price on Chemours to $66.00 and gave the company a “buy” rating in a research report on Monday, December 4th. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $57.95.

Chemours (NYSE CC) traded up $0.26 during midday trading on Wednesday, hitting $50.24. The stock had a trading volume of 250,484 shares, compared to its average volume of 1,786,368. Chemours has a fifty-two week low of $32.31 and a fifty-two week high of $58.08. The stock has a market cap of $9,190.00 and a PE ratio of 9.63. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 4.74.

Chemours (NYSE:CC) last announced its earnings results on Wednesday, February 14th. The specialty chemicals company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.24. Chemours had a return on equity of 115.54% and a net margin of 12.06%. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.55 billion. During the same period last year, the business posted $0.08 EPS. Chemours’s revenue for the quarter was up 19.1% on a year-over-year basis. analysts expect that Chemours will post 5.3 EPS for the current fiscal year.

Chemours declared that its board has approved a stock repurchase program on Friday, December 1st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the specialty chemicals company to buy shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

In related news, insider Paul Kirsch sold 13,770 shares of Chemours stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $50.01, for a total value of $688,637.70. Following the sale, the insider now directly owns 63,093 shares in the company, valued at $3,155,280.93. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Mark Newman sold 29,381 shares of Chemours stock in a transaction on Friday, March 9th. The stock was sold at an average price of $49.19, for a total value of $1,445,251.39. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Chemours (NYSE:CC) Earning Somewhat Favorable Press Coverage, Report Finds” was posted by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-chemours-cc-stock-price/1889766.html.

Chemours Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Insider Buying and Selling by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.